Approach

Summary

Licensing status

Publication and contact information

Markers

Solute carrier family 12
potassium-chloride transporter member 2
(SLC12A2; NKCC1)-based markers for schizophrenia

Genetic profiling studies suggest assessing variation in NKCC1 expression could help predict schizophrenia risk. NKCC1 is expressed as two alternative splice variants-NKCC1a and NKCC1b-and as an ultra-short transcript. Sequencing and analysis of postmortem brain tissue samples showed that schizophrenia patients had lower expression of the NKCC1b and ultra-short transcripts than controls without psychiatric disorders. The rs3087889 SNP in NKCC1 was associated with decreased NKCC1b expression and increased risk of schizophrenia. Next steps could include validating the various NKCC1-based markers in larger patient cohorts.

SciBX 7(17); doi:10.1038/scibx.2014.509
Published online May 1, 2014

Patent and licensing status unavailable

Morita, Y. et al. J. Neurosci.; published online April 2, 2014;
doi:10.1523/JNEUROSCI.1423-13.2014
Contact: Thomas M. Hyde, Lieber Institute for Brain Development, Baltimore, Md.
e-mail:

thomas.hyde@libd.org